IDH1 and central nervous system cancer: From a metabolic perspective, in IDH-mutant gliomas, isocitrate is not converted to α-ketoglutarate (α-KG) as usual but is converted to a new signature metabolite, 2-hydroxyglutarate (2-HG) (34).